Targeting Histone Deacetylase in Focal Segmental Glomerulosclerosis - From Mice to Patients
Abstract
Glomerular diseases account for approximately 80 percent of end stage kidney disease (ESKD). Nearly 600,000 US residents have end-stage kidney disease (ESKD) at an annual Medicare expenditure of 28 billion dollars. Through RNA profiling in our models of FSGS, we have found that HDAC activity is increased in the glomerulus and blocking with HDAC inhibitor, valproic acid or suberanilohydroxamic acid mitigates progression of kidney disease. During the last funding period, we have generated podocyte specific knockout mice for HDAC1 and 2, which also appears protective against glomerular injury in toxin mediated and genetic mouse models. In parallel, our collaborator for this study, Perry Wilson have continued to examine Veterans Affairs Cohort and discerned protective benefit for proteinuric patients who happened to be on VPA.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2018
- Accession Number
- AD1063031
Entities
People
- Francis P. Wilson
- Shuta Ishibe
Organizations
- Yale University